# Estimated Vaccine Effectiveness and Durability of Pfizer/BioNTech 2024-2025 COVID-19 Vaccine

> **NCT06703190** · — · TERMINATED · sponsor: **Pfizer** · enrollment: 1 (actual)

## Conditions studied

- COVID-19

## Interventions

- **BIOLOGICAL:** Pfizer-BioNTech BNT162b2 COVID-19 Vaccinated
- **BIOLOGICAL:** Not vaccinated with 2024-2025 formulated COVID-19 vaccine

## Key facts

- **NCT ID:** NCT06703190
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2024-11-25
- **Primary completion:** 2025-06-06
- **Final completion:** 2025-06-06
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** This secondary data analysis of symptomatic CVS MinuteClinics patients testing for SARS-CoV-2 was terminated due to incomplete data on KP.2 vaccination status (exposure). Termination was not based on any safety concerns or regulatory requirements.
- **Last updated:** 2025-11-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06703190

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06703190, "Estimated Vaccine Effectiveness and Durability of Pfizer/BioNTech 2024-2025 COVID-19 Vaccine". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06703190. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*